Agios Pharmaceuticals Reports Third Quarter 2014 Financial Results
November 07, 2014 07:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 7, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today reported...
Agios Pharmaceuticals to Present Clinical and Preclinical Data at the 2014 American Society of Hematology Annual Meeting
November 06, 2014 09:07 ET
|
Agios Pharmaceuticals, Inc.
New Data from Ongoing Phase 1 AG-221 Trial Accepted for Oral Presentation
Poster Presentation to Reveal First Clinical Data for AG-348, a Potential Treatment for Pyruvate Kinase Deficiency...
Agios Pharmaceuticals to Webcast Conference Call of Third Quarter 2014 Financial Results on November 7, 2014
October 27, 2014 08:30 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced...
Agios Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of AG-221 in Patients with Advanced Solid Tumors with an IDH2 Mutation
October 21, 2014 08:30 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Oct. 21, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced the...
Agios Pharmaceuticals Announces Initiation of Four Expansion Cohorts in Phase 1 Study of AG-221
October 15, 2014 07:30 ET
|
Agios Pharmaceuticals, Inc.
Once-Daily Oral Dose Selected From Ongoing Phase 1 Study of AG-221 in Hematologic Malignancies
Data From AG-120 to be Presented at EORTC-NCI-AACR 2014; AG-221 and AG-348 Data to be Presented at...
Agios Pharmaceuticals to Webcast R&D Day on October 15, 2014
October 06, 2014 09:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Oct. 6, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that...
Agios Pharmaceuticals to Present at the 2014 Leerink Partners Rare Disease Roundtable
September 23, 2014 16:05 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 23, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced...
Agios Pharmaceuticals Announces the U.S. FDA Grants Fast Track Designation to AG-221 for Treatment of Patients With Acute Myelogenous Leukemia That Harbor an IDH2 Mutation
August 13, 2014 08:30 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Aug. 13, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced...
Agios Pharmaceuticals Reports Second Quarter 2014 Financial Results
August 07, 2014 07:30 ET
|
Agios Pharmaceuticals, Inc.
- AG-221: Company on track to start four Phase 1 expansion cohorts in second half of 2014; abstract of additional Phase 1 data submitted to the 2014 ASH Annual Meeting -
- AG-348: Phase 1 healthy...
Agios Pharmaceuticals to Webcast Conference Call of Second Quarter 2014 Financial Results on August 7, 2014
July 28, 2014 09:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., July 28, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced that it will...